Growth Metrics

Insight Molecular Diagnostics (IMDX) Income towards Parent Company: 2015-2024

Historic Income towards Parent Company for Insight Molecular Diagnostics (IMDX) over the last 10 years, with Dec 2024 value amounting to -$61.0 million.

  • Insight Molecular Diagnostics' Income towards Parent Company rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 41.10%. This contributed to the annual value of -$61.0 million for FY2024, which is 1986.16% down from last year.
  • According to the latest figures from FY2024, Insight Molecular Diagnostics' Income towards Parent Company is -$61.0 million, which was down 1,986.16% from -$2.9 million recorded in FY2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Income towards Parent Company peaked at -$2.9 million during FY2023, and registered a low of -$61.0 million during FY2024.
  • Moreover, its 3-year median value for Income towards Parent Company was -$54.3 million (2022), whereas its average is -$39.4 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Income towards Parent Company spiked by 94.61% in 2023, and later tumbled by 1,986.16% in 2024.
  • Yearly analysis of 5 years shows Insight Molecular Diagnostics' Income towards Parent Company stood at -$29.9 million in 2020, then spiked by 31.45% to -$20.5 million in 2021, then crashed by 165.00% to -$54.3 million in 2022, then skyrocketed by 94.61% to -$2.9 million in 2023, then plummeted by 1,986.16% to -$61.0 million in 2024.